Skip to main content

Advertisement

Table 3 Screening of the potential covariates for overall survival using the Cox model

From: Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

  HR 95 % CI Score p Sign on risk
TTG (weeks) 0.83a 0.81–0.85a 151.7 <0.0001
Tumor size at randomization (cm) 1.17b 1.13–1.20b 51.8 <0.0001 +
Week 8 ECTS 1.12c 1.10–1.14c 45.1 <0.0001 +
Female 0.64 0.56–0.74 21.2 <0.0001
Never smoked 0.57 0.47–0.68 20.3 <0.0001
Asian 0.61 0.50–0.75 12.5 <0.0001
Study SATURN 1.33 1.16–1.51 9.2 <0.0001 +
ECOG score >0 1.30 1.14–1.49 7.7 0.0001 +
Age ≥ 55 years 1.23 1.07–1.42 4.2 0.0037 +
Squamous 1.22 1.06–1.40 3.8 0.0060 +
Erlotinib 0.85 0.75–0.96 3.5 0.0082
Erlotinib in SD 0.84 0.73–0.97 3 0.0144
Age (years) 1.07d 1.01–1.14d 2.6 0.0221 +
  1. CI confidence interval, ECTS early change in tumor size, Erlotinib patients who received erlotinib during the first-line treatment run-in phase (all patients were analyzed), Erlotinib in SD patients who received erlotinib during the first-line treatment phase (only those patients who achieved stable disease during first-line treatment run-in phase were analyzed), HR hazard ratio, p obtained by likelihood ratio test, Score log(likelihood ratio), Sign on risk + (−) indicates that this variable is associated with increased (decreased) risk, TTG time to tumor regrowth, aHR for increase of every 8 weeks of TTG; bHR for increase of every 2 cm of tumor size at randomization; cHR for increase in every 10 % of tumor size as compared to the randomization; dHR for increase of every 10 years of age